Novartis Reports Q2 Sales Growth and Reaffirms Full-Year Outlook
Novartis reported a return to sales growth in the second quarter of 2026 with net sales rising by 1% year-over-year to $14.4 billion, driven primarily by strong performance from key medicines like KISQALI and Pluvicto. The company reaffirmed its full-year outlook despite ongoing U.S. generic erosion affecting Entresto.
Tickers: $NVS